Biomarin Stock Falls On Unusually High Volume (BMRN)
Biomarin Pharmaceutical (Nasdaq:BMRN) is trading at unusually high volume Thursday with 2.5 million shares changing hands. It is currently at two times its average daily volume and trading down $3.31 (-4.9%).
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Biomarin Pharmaceutical (Nasdaq: BMRN) is trading at unusually high volume Thursday with 2.5 million shares changing hands. It is currently at two times its average daily volume and trading down $3.31 (-4.9%) at $64.50 as of 3:40 p.m. ET.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Biomarin has a market cap of $9.77 billion and is part of the health care sector and drugs industry. Shares are up 42.9% year to date as of the close of trading on Wednesday. BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. TheStreet Ratings rates Biomarin as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full Biomarin Ratings Report. See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.